OAM
HEPA

Oxford Asset Management’s Hepion Pharmaceuticals HEPA Stock Holding History

Oxford Asset Management’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17
Closed -$92K – 682
2019
Q4 		$92K Buy
+17
New +$65.8K ﹤0.01% 1622

Other funds holding HEPA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oxford Asset Management's HEPA Position: Q1 2020 in Review

Oxford Asset Management sold out of Hepion Pharmaceuticals (HEPA) in Q1 2020, closing a stake of 17 shares — an estimated $92K sold.

Oxford Asset Management first reported a position in HEPA in Q4 2019 and held it in 1 quarter. The position peaked at $92K in Q4 2019. 6 funds tracked by Wall St. Rank hold HEPA as of Q1 2020.

  • Oxford Asset Management reported no remaining Hepion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 17 Hepion Pharmaceuticals shares in Q1 2020, an estimated $92K.
  • Oxford Asset Management first reported a position in Hepion Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Oxford Asset Management's Hepion Pharmaceuticals position peaked at $92K in Q4 2019.
  • 6 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.